United States · Amendment · HAMDT
HAMDT 233 (109th)
An amendment to insert a new section providing authority for the Secretary to require that the manufacturer of an approved drug conduct one or more studies to confirm or refute an empirical or theoretical hypothesis of a significant safety issue with the drug.
Introduced
—
Last action
—
Status
Mr. Bonilla raised a point of order against the Hinchey amendment (A010). Mr. Bonilla stated that the provisions of the Hinchey amendment seek to change existing law and constitute legislation in an appropriations bill. The Chair sustained the point of order.
Sponsors
Rep. Hinchey, Maurice D. [D-NY-22]
Subjects
Discovery layer
Source updated
25 February 2022
Records
Official amendment HAMDT 233 (109th) from United States at United States Congress. Status: Mr. Bonilla raised a point of order against the Hinchey amendment (A010). Mr. Bonilla stated that the provisions of the Hinchey amendment seek to change existing law and constitute legislation in an appropriations bill. The Chair sustained the point of order..
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Hinchey, Maurice D. [D-NY-22] · D · Sponsor
Related records
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/amendment/109th-congress/hamdt-233
- Open data entity: https://api.congress.gov/v3/amendment/109/hamdt/233
- us · 109-hamdt-233 · source updated 25 February 2022